Insulin Resistance Market Size, Emerging Therapies, and Forecast Insights Through 2036 - DelveInsight

DelveInsight's report "Insulin Resistance Market Insights, Epidemiology, and Market Forecast-2036," provides a comprehensive analysis of the Insulin Resistance landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions.

Additionally, it examines Insulin Resistance market dynamics, offering a thorough assessment of current and emerging market trends, treatment patterns, and therapeutic developments. The analysis spans major markets, including the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom), and Japan, equipping decision-makers with actionable intelligence for strategic planning, investment, and research initiatives.

To Know in detail about the Insulin Resistance market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Insulin Resistance Market Forecast
https://www.delveinsight.com/sample-request/insulin-resistance-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav

Some of the key facts of the Insulin Resistance Market Report:
• The Insulin Resistance market size is anticipated to grow with a significant CAGR during the study period (2022-2036).
• Insulin resistance represents a major and growing global public health burden, closely linked to the rising prevalence of obesity, type 2 diabetes mellitus (T2DM), and cardio metabolic risk factors. Globally, the pooled prevalence of Insulin resistance was estimated at 26.53% in 2025, underscoring its widespread impact across populations.
• Recent prevalence estimates indicate that total Insulin resistance prevalence in the United States is 29.5%, with a higher burden in men (53.2%) compared with women (46.8%). Secondary analysis demonstrates a rising and sustained prevalence of insulin resistance among adults.
• In 2003, approximately 22% of US adults aged >20 years were insulin-resistant. Data from 2021 indicate that ~40% of US adults aged 18-44 years are insulin resistant based on HOMA-IR criteria, confirming a significant shift toward younger age groups.
• In the UK, insulin resistance affects ~37% of adults as of 2025, rising from 28% in 2022, with the most rapid growth seen in individuals aged 30-45 years, where prevalence has nearly doubled
• In the US, insulin resistance drives 70-90% of type 2 diabetes cases via beta-cell exhaustion and precedes metabolic syndrome in 25-40% of affected adults. It accounts for 60-80% of NAFLD and 30-50% of cardiovascular risk. These global data highlight insulin resistance as a primary target for preventing diabetes, NAFLD, CVD, and PCOS worldwide.
• Among European countries, Spain exhibited the highest prevalence of insulin resistance, with an overall prevalence of 30.4%. In France, the overall prevalence is 26.0%, with higher prevalence in men (62.7%) compared with women (37.3%). In Japan, total insulin resistance prevalence is 25.5%, with similar rates between women and men.
• Key Insulin Resistance Companies: Corbus Pharmaceuticals Holdings, Inc., Kura Oncology, Inc, SCOHIA Pharma Inc, Atrogi, YUNOVIA CO.,LTD., PegBio, Eli Lilly and Company, Tonix Pharma, Pfizer, OrsoBio, Dompe Farmaceutici, GlaxoSmithKline, J. Uriach and Company, Boehringer Ingelheim, Eli Lilly and Company, Genfit, Novartis, Daiichi Sankyo, Inc., and others
• Key Insulin Resistance Therapies: CRB-913, Ziftomenib, SCO-240, ATR-258, ID110521156, Visepegenatide (PB-119), Retatrutide, TNX-1900, Steglatro, TLC-3595, Ladarixin, Avandia, Triflusal (DCI), MICARDIS® (telmisartan), U-500 insulin, Vildagliptin, GFT505, Nateglinide, Olmesartan medoxomil, and others
• The Insulin Resistance epidemiology based on gender analyzed that most of the Insulin Resistance cases comprise of the female population
• The Insulin Resistance market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Insulin Resistance pipeline products will significantly revolutionize the Insulin Resistance market dynamics.

Insulin Resistance Overview
Insulin Resistance (NK) is a rare, degenerative eye disease caused by damage to the corneal nerves, leading to reduced corneal sensitivity. This loss of sensation impairs the cornea's ability to heal, resulting in persistent epithelial defects, corneal ulcers, and in severe cases, vision loss. Common causes include herpetic infections, diabetes, ocular surgeries, and neurological disorders. Early diagnosis and timely treatment are critical to prevent progression and preserve vision, often involving lubricating eye drops, therapeutic contact lenses, or novel regenerative therapies.

Get a Free sample for the Insulin Resistance Market Report:
https://www.delveinsight.com/report-store/insulin-resistance-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav

Insulin Resistance Epidemiology
The Insulin Resistance epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Insulin Resistance Epidemiology Segmentation:
The Insulin Resistance market report proffers epidemiological analysis for the study period 2022-2036 in the 7MM segmented into:
• Total Prevalent cases of Insulin resistance in the 7MM
• Total Diagnosed Prevalent cases of Insulin resistance in the 7MM
• Age-specific cases of Insulin resistance in the 7MM
• Total Diagnosed Prevalent cases of Insulin resistance in the 7MM
• Gender-specific cases of Insulin resistance in the 7MM
• Comorbidity-specific cases of Insulin resistance in the 7MM Treated cases of Insulin resistance in the 7MM

Download the report to understand which factors are driving Insulin Resistance epidemiology trends @ Insulin Resistance Epidemiology Forecast
https://www.delveinsight.com/sample-request/insulin-resistance-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav

Insulin Resistance Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Insulin Resistance market or expected to get launched during the study period. The analysis covers Insulin Resistance market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Insulin Resistance Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Insulin Resistance Therapies and Key Companies
• CRB-913: Corbus Pharmaceuticals Holdings, Inc.
• Ziftomenib: Kura Oncology, Inc
• SCO-240: SCOHIA Pharma Inc
• ATR-258: Atrogi
• ID110521156: YUNOVIA CO.,LTD.
• Visepegenatide (PB-119): PegBio
• Retatrutide: Eli Lilly and Company
• TNX-1900: Tonix Pharmaceuticals
• Steglatro: Pfizer
• TLC-3595: OrsoBio
• Ladarixin: Dompe Farmaceutici
• Avandia: GlaxoSmithKline
• Triflusal (DCI): J. Uriach and Company
• MICARDIS® (telmisartan): Boehringer Ingelheim
• U-500 insulin: Eli Lilly and Company
• Vildagliptin: Novartis
• GFT505: Genfit
• Nateglinide: Novartis
• Olmesartan medoxomil: Daiichi Sankyo, Inc.

Discover more about therapies set to grab major Insulin Resistance market share @ Insulin Resistance Treatment Market
https://www.delveinsight.com/sample-request/insulin-resistance-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav

Insulin Resistance Market Drivers
• Increasing prevalence of corneal disorders, diabetes, ocular surgeries, and chronic eye surface diseases contributing to NK cases.
• Advancements in early diagnosis and improved awareness among ophthalmologists facilitating timely intervention.
• Introduction and adoption of novel therapies, such as recombinant human nerve growth factor (rhNGF), enhancing treatment outcomes.
• Strong clinical pipeline and ongoing R&D in regenerative therapies, biologics, and advanced wound-healing agents.
• Expanded healthcare infrastructure and reimbursement support improving patient access to advanced NK treatments.

Insulin Resistance Market Barriers
• Limited awareness of NK in some regions leading to delayed diagnosis and treatment.
• High treatment costs, particularly for advanced biologics, restricting patient accessibility.
• Small patient population classified as orphan disease, limiting commercial incentives for major pharmaceutical companies.
• Complexity of disease management requiring specialized ophthalmology expertise.
• Regulatory challenges and long development timelines for novel therapies may slow market growth.

Scope of the Insulin Resistance Market Report
• Study Period: 2022-2036
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Insulin Resistance Companies: Corbus Pharmaceuticals Holdings, Inc., Kura Oncology, Inc, SCOHIA Pharma Inc, Atrogi, YUNOVIA CO.,LTD., PegBio, Eli Lilly and Company, Tonix Pharma, Pfizer, OrsoBio, Dompe Farmaceutici, GlaxoSmithKline, J. Uriach and Company, Boehringer Ingelheim, Eli Lilly and Company, Genfit, Novartis, Daiichi Sankyo, Inc., and others
• Key Insulin Resistance Therapies: CRB-913, Ziftomenib, SCO-240, ATR-258, ID110521156, Visepegenatide (PB-119), Retatrutide, TNX-1900, Steglatro, TLC-3595, Ladarixin, Avandia, Triflusal (DCI), MICARDIS® (telmisartan), U-500 insulin, Vildagliptin, GFT505, Nateglinide, Olmesartan medoxomil, and others
• Insulin Resistance Therapeutic Assessment: Insulin Resistance current marketed and Insulin Resistance emerging therapies
• Insulin Resistance Market Dynamics: Insulin Resistance market drivers and Insulin Resistance market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Insulin Resistance Unmet Needs, KOL's views, Analyst's views, Insulin Resistance Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.